Genotype and risk of tumour rupture in gastrointestinal stromal tumour.

about

Genotype and risk of tumour rupture in gastrointestinal stromal tumour.

Item

http://www.wikidata.org/entity/Q48229455

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Genotype and risk of tumour rupture in gastrointestinal stromal tumour.

@en

Genotype and risk of tumour rupture in gastrointestinal stromal tumour.

@nl

type

Item

label

Genotype and risk of tumour rupture in gastrointestinal stromal tumour.

@en

Genotype and risk of tumour rupture in gastrointestinal stromal tumour.

@nl

prefLabel

Genotype and risk of tumour rupture in gastrointestinal stromal tumour.

@en

Genotype and risk of tumour rupture in gastrointestinal stromal tumour.

@nl

P1476

Genotype and risk of tumour rupture in gastrointestinal stromal tumour.

@en

P2093

B Bjerkehagen

http://www.w3.org/2001/XMLSchema#string

I Hompland

http://www.w3.org/2001/XMLSchema#string

J-M Berner

http://www.w3.org/2001/XMLSchema#string

K Sundby Hall

http://www.w3.org/2001/XMLSchema#string

S Stoldt

http://www.w3.org/2001/XMLSchema#string

P2860

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial

Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors.

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

Prognosis and predictive value of KIT exon 11 deletion in GISTs.

Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour.

P304

e169-e175

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/BJS.10743

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Øyvind Sverre Bruland

Kjetil Boye

T Hølmebakk

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29341147

http://www.w3.org/2001/XMLSchema#string